Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566202 · ClinicalTrials.gov registry record · Phase 2
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00566202 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 67 participants.
The verdict
NCT00566202, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG JNJ-18038683
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566202
The ClinicalTrials.gov registry entry for NCT00566202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00566202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566202 about?
NCT00566202 is a clinical study titled "A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression". The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.
What is the current status of trial NCT00566202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2007-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00566202?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), JNJ-18038683 (DRUG).
Who is sponsoring clinical trial NCT00566202?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.